Recruiting
An Investigational Immuno-therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Patients With Solid Cancers That Are Advanced or Have Spread - CA012-004
Updated: 10 December, 2019 | ClinicalTrials.gov
Print Friendly Summary
Trial Details
Phase
Gender(s)
Age Range
Location(s)
Recruiting
Treatment Options
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Patients must have at least 1 standard treatment regimen in the advanced, recurrent or metastatic setting - ECOG (Eastern Cooperative Oncology Group) 0-1 - Men and women 18 years old or older - At least one measurable lesion at baseline by CT (computed tomography) or MRI (magnetic resonance imaging) as per RECIST (Response Evaluation Criteria In Solid Tumors) v1.1 - All subjects must have a fresh tumor biopsy Exclusion Criteria: - Known central nervous system metastases or central nervous system as the only source of disease - Concomitant malignancies - Active known or suspected autoimmune disease - Uncontrolled or significant cardiovascular disease - Major surgery less than 4 weeks before the start of the study - Patients with known allergies to egg products, neomycin, or tetanus toxoid - Prior adverse reaction to tetanus toxoid-containing vaccines Other protocol defined inclusion/exclusion criteria could apply
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information
